NEW YORK – Nucleome Therapeutics on Tuesday said it has entered into a research collaboration with Johnson & Johnson to study genetic associations linked to autoimmune diseases.
Ultimately, Nucleome and J&J aim to discover new target genes and cell types that drive autoimmune diseases, which could help to identify patients that are more likely to respond to therapy.
"We are delighted to be working with J&J to identify new targets and develop strategies for patient stratification in autoimmune disease," Nucleome CSO Stephen Harrison said in a statement.
Oxford, UK-based Nucleome will use machine learning and its 3D genomics technologies to define specific genetic differences that make patients susceptible to certain autoimmune diseases and determine the mechanisms that underlie those diseases, while J&J will contribute its immunology and data sciences capabilities to the collaboration.
Nucleome was founded in 2019 as a spinout from the University of Oxford and since then has refined an approach to map 3D genome structure down to a single base pair.